Clinical trials: Second-Line
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell…
- Trial name
- NCT03370159
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Biliary Tract Cancer (BTC)
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
The purpose of this study is to explore the effects of sacituzumab tirumotecan combined with pembrolizumab on survival, disease progression, and safety in patients with advanced biliary tract malignancies in the second-line and…
- Trial name
- NCT07850791
- Testing
- Sacituzumab Tirumotecan (SKB264), Pembrolizumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Haitao Zhao, MD
Small Cell Lung Carcinoma
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
The primary aim of this study is to determine if the addition of valproic acid to a combination of adriamycin, cyclophosphamide and vindesine could increase progression-free survival in patients relapsing after first-line…
- Trial name
- NCT00759824
- Testing
- Adriamycin, cyclophosphamide, vindesine, valproic acid
- Where
- 5 sites in Belgium
- Volunteers
- 64 people
- Sponsor
- European Lung Cancer Working Party
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER
Management and Leadership in Healthcare
Management and Leadership in Healthcare: Expectations, Conditions, Skills, and Reflections in a Leadership Program
This study follows first- and second-line healthcare managers who take part in an established leadership development program in a Swedish healthcare region.
- Trial name
- NCT07678905
- Testing
- Leadership Development Program
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Kronoberg County Council
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00454194
- Testing
- pemetrexed disodium, sorafenib tosylate
- Where
- 207 sites in United States
- Volunteers
- 110 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated activity, but no agent is clearly superior.
- Trial name
- GIM11-BERGI (NCT02175446)
- Testing
- Bevacizumab and eribulin
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Consorzio Oncotech
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Clear Cell Renal Cell Carcinoma
Combination of Toripalimab and JS004 Therapy for ccRCC
This study is a single center, prospective, randomized controlled phase II clinical trial aimed at examining the efficacy and safety of the combination of toripalimab and JS004 versus standard therapy for second-line treatment of…
- Trial name
- NCT06690697
- Testing
- JS004, Toripalimab, Axitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Locally Recurrent or Metastatic Breast Cancer
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or…
- Trial name
- NCT01256762
- Testing
- Imetelstat sodium, Bevacizumab, Paclitaxel
- Where
- 55 sites in United States, Canada
- Volunteers
- 166 people
- Sponsor
- Geron Corporation
Hodgkin Lymphoma, Adult, Relapse
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles.
- Conditions
- Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma
- Trial name
- NCT05137886
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Breast Cancer (Advanced/Metastatic), ER Positive
Blood Biomarkers for Breast Cancer Treatment Response
This study looks at whether a simple blood test can help predict how well a breast cancer treatment will work. It follows patients with advanced hormone receptor-positive breast cancer whose cancer has progressed after their…
- Trial name
- TrackER (NCT07860866)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Tumor, Colorectal Cancer
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Study 07-PIR-02 is a Phase 2 study designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with colorectal cancer (CRC).
- Trial name
- NCT00598975
- Testing
- NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002937
- Testing
- paclitaxel, valspodar
- Where
- 4 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-Cell Lymphoma
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
This is a randomised, phase II open-labelled two-arm study comparing R-GEM-P and LR-GEM in second-line treatment of Diffuse Large B-cell lymphoma. Eligible patients will be randomised 1:1 between R-GEM-P and LR-GEM.
- Trial name
- LEGEND (NCT02060656)
- Testing
- Gemcitabine, Methylprednisolone, Rituximab
- Where
- United Kingdom
- Volunteers
- 92 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Adenocarcinoma, Scirrhous, Linitis Plastica
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
This is a prospective, open-label, single-arm, non-randomized, multi-center, phase II proof of concept (PoC) study with a two-stage design and Bayesian interim monitoring to evaluate efficacy and safety of single agent TKI258 in…
- Conditions
- Adenocarcinoma, Scirrhous, Linitis Plastica, Stomach Neoplasms, Stomach Diseases
- Trial name
- NCT01576380
- Testing
- TKI258
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
The purpose of this interventional study is to investigate whether there is evidence that panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will safely increase progression-free survival, above…
- Trial name
- VOXEL (NCT00950820)
- Testing
- Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- AIO-Studien-gGmbH
Treatment Failure of Second-line ART in Asian HIV-infected Children
Second-line Therapy
This study will help identify which ARV candidates should be prioritized for pediatric use in resource-limited settings
- Trial name
- TASER-P (NCT01788891)
- Where
- 8 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 300 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.